Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Michinori Ogura, Takashi Ishida, Kiyohiko Hatake, et al.
Journal of Clinical Oncology (2014) Vol. 32, Iss. 11, pp. 1157-1163
Open Access | Times Cited: 337

Showing 1-25 of 337 citing articles:

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou, Jedd D. Wolchok, Lieping Chen
Science Translational Medicine (2016) Vol. 8, Iss. 328
Open Access | Times Cited: 2122
Inflammation and tumor progression: signaling pathways and targeted intervention
Huakan Zhao, Lei Wu, Guifang Yan, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1599
Coinhibitory Pathways in Immunotherapy for Cancer
Susanne H.C. Baumeister, Gordon J. Freeman, Glenn Dranoff, et al.
Annual Review of Immunology (2016) Vol. 34, Iss. 1, pp. 539-573
Closed Access | Times Cited: 830
CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells
Alan L. Chang, Jason Miska, Derek A. Wainwright, et al.
Cancer Research (2016) Vol. 76, Iss. 19, pp. 5671-5682
Open Access | Times Cited: 532
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting
Belal Chaudhary, Eyad Elkord
Vaccines (2016) Vol. 4, Iss. 3, pp. 28-28
Open Access | Times Cited: 435
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017
Franz Trautinger, Johanna Eder, Chalid Assaf, et al.
European Journal of Cancer (2017) Vol. 77, pp. 57-74
Open Access | Times Cited: 419
Analyses of repeated failures in cancer therapy for solid tumors: poor tumor‐selective drug delivery, low therapeutic efficacy and unsustainable costs
Hiroshi Maeda, Mahin Khatami
Clinical and Translational Medicine (2018) Vol. 7, Iss. 1
Open Access | Times Cited: 416
CCR4 and its ligands: from bench to bedside
Osamu Yoshie, Kouji Matsushima
International Immunology (2014) Vol. 27, Iss. 1, pp. 11-20
Open Access | Times Cited: 360
Key chemokines direct migration of immune cells in solid tumors
Karan Kohli, Venu G. Pillarisetty, Teresa S. Kim
Cancer Gene Therapy (2021) Vol. 29, Iss. 1, pp. 10-21
Open Access | Times Cited: 348
CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4
Jan Korbecki, Klaudyna Kojder, Donata Simińska, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 8412-8412
Open Access | Times Cited: 325
Regulatory T cells in the treatment of disease
Amir Sharabi, Maria Tsokos, Ying Ding, et al.
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 11, pp. 823-844
Open Access | Times Cited: 263
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project
Youn H. Kim, Mahkam Tavallaee, Uma Sundram, et al.
Journal of Clinical Oncology (2015) Vol. 33, Iss. 32, pp. 3750-3758
Open Access | Times Cited: 258
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Carla Riera‐Domingo, Annette Audigé, Sara Granja, et al.
Physiological Reviews (2019) Vol. 100, Iss. 1, pp. 1-102
Open Access | Times Cited: 251
Dose‐intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: a randomized phase II study
Takashi Ishida, Tatsuro Jo, Shigeki Takemoto, et al.
British Journal of Haematology (2015) Vol. 169, Iss. 5, pp. 672-682
Open Access | Times Cited: 236
Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Rein Willemze, Emmilia Hodak, Pier Luigi Zinzani, et al.
Annals of Oncology (2018) Vol. 29, pp. iv30-iv40
Open Access | Times Cited: 230
Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma
Madeleine Duvic, Lauren Pinter‐Brown, Francine M. Foss, et al.
Blood (2015) Vol. 125, Iss. 12, pp. 1883-1889
Open Access | Times Cited: 215
Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Francesco d’Amore, Philippe Gaulard, Lorenz Trümper, et al.
Annals of Oncology (2015) Vol. 26, pp. v108-v115
Open Access | Times Cited: 198
Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
Catherine J. Hutchings, Markus Koglin, William C. Olson, et al.
Nature Reviews Drug Discovery (2017) Vol. 16, Iss. 11, pp. 787-810
Closed Access | Times Cited: 180
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
John P. Veluchamy, Nina Kok, Hans van Vliet, et al.
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 178
Targeting cytokine and chemokine signaling pathways for cancer therapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 49
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges
Chrisann Kyi, Michael A. Postow
Immunotherapy (2016) Vol. 8, Iss. 7, pp. 821-837
Open Access | Times Cited: 150
Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
Mohamed A. Kharfan‐Dabaja, Ambuj Kumar, Ernesto Ayala, et al.
Biology of Blood and Marrow Transplantation (2017) Vol. 23, Iss. 11, pp. 1826-1838
Open Access | Times Cited: 144
Cutaneous T‐cell lymphoma: 2017 update on diagnosis, risk‐stratification, and management
Ryan A. Wilcox
American Journal of Hematology (2017) Vol. 92, Iss. 10, pp. 1085-1102
Open Access | Times Cited: 141
Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sézary Syndrome
Xiao Ni, Jeffrey L. Jorgensen, Meghali Goswami, et al.
Clinical Cancer Research (2014) Vol. 21, Iss. 2, pp. 274-285
Open Access | Times Cited: 139
Cutaneous T‐cell lymphoma: 2016 update on diagnosis, risk‐stratification, and management
Ryan A. Wilcox
American Journal of Hematology (2015) Vol. 91, Iss. 1, pp. 151-165
Open Access | Times Cited: 139
Page 1 - Next Page

Scroll to top